Identification of diseases based on the use of inertial sensors: a systematic review

Inertial sensors are commonly embedded in several devices, including smartphones, and other specific devices. This type of sensors may be used for different purposes, including the recognition of different diseases. Several studies are focused on the use of accelerometer for the automatic recognition of different diseases, and it may powerful the different treatments with the use of less invasive and painful techniques for patients. This paper is focused in the systematic review of the studies available in the literature for the automatic recognition of different diseases with accelerometer sensors. The disease that is the most reliably detectable disease using accelerometer sensors, available in 54% of the analyzed studies, is the Parkinson’s disease. The machine learning methods implements for the recognition of Parkinson’s disease reported an accuracy of 94%. Other diseases are recognized in less number that will be subject of further analysis in the future.info:eu-repo/semantics/publishedVersio

Neurological Tremor: Sensors, Signal Processing and Emerging Applications

Neurological tremor is the most common movement disorder, affecting more than 4% of elderly people. Tremor is a non linear and non stationary phenomenon, which is increasingly recognized. The issue of selection of sensors is central in the characterization of tremor. This paper reviews the state-of-the-art instrumentation and methods of signal processing for tremor occurring in humans. We describe the advantages and disadvantages of the most commonly used sensors, as well as the emerging wearable sensors being developed to assess tremor instantaneously. We discuss the current limitations and the future applications such as the integration of tremor sensors in BCIs (brain-computer interfaces) and the need for sensor fusion approaches for wearable solutions

Wearable feedback systems for rehabilitation

In this paper we describe LiveNet, a flexible wearable platform intended for long-term ambulatory health monitoring with real-time data streaming and context classification. Based on the MIT Wearable Computing Group's distributed mobile system architecture, LiveNet is a stable, accessible system that combines inexpensive, commodity hardware; a flexible sensor/peripheral interconnection bus; and a powerful, light-weight distributed sensing, classification, and inter-process communications software architecture to facilitate the development of distributed real-time multi-modal and context-aware applications. LiveNet is able to continuously monitor a wide range of physiological signals together with the user's activity and context, to develop a personalized, data-rich health profile of a user over time. We demonstrate the power and functionality of this platform by describing a number of health monitoring applications using the LiveNet system in a variety of clinical studies that are underway. Initial evaluations of these pilot experiments demonstrate the potential of using the LiveNet system for real-world applications in rehabilitation medicine

Updates of Wearing Devices (WDs) In Healthcare, And Disease Monitoring

 With the rising pervasiveness of growing populace, aging and chronic illnesses consistently rising medical services costs, the health care system is going through a crucial change from the conventional hospital focused system to an individual-focused system. Since the twentieth century, wearable sensors are becoming widespread in medical care and biomedical monitoring systems, engaging consistent estimation of biomarkers for checking of the diseased condition and wellbeing, clinical diagnostics and assessment in biological fluids like saliva, blood, and sweat. Recently, the improvements have been centered around electrochemical and optical biosensors, alongside advances with the non-invasive monitoring of biomarkers, bacteria and hormones, etc. Wearable devices have created with a mix of multiplexed biosensing, microfluidic testing and transport frameworks incorporated with flexible materials and body connections for additional created wear ability and effortlessness. These wearables hold guarantee and are fit for a higher understanding of the relationships between analyte focuses inside the blood or non-invasive biofluids and feedback to the patient, which is fundamentally significant in ideal finding, therapy, and control of diseases. In any case, cohort validation studies and execution assessment of wearable biosensors are expected to support their clinical acceptance. In the current review, we discussed the significance, highlights, types of wearables, difficulties and utilizations of wearable devices for biological fluids for the prevention of diseased conditions and real time monitoring of human wellbeing. In this, we sum up the different wearable devices that are developed for health care monitoring and their future potential has been discussed in detail

Entropy-based machine learning model for diagnosis and monitoring of Parkinson's Disease in smart IoT environment

The study presents the concept of a computationally efficient machine learning (ML) model for diagnosing and monitoring Parkinson's disease (PD) in an Internet of Things (IoT) environment using rest-state EEG signals (rs-EEG). We computed different types of entropy from EEG signals and found that Fuzzy Entropy performed the best in diagnosing and monitoring PD using rs-EEG. We also investigated different combinations of signal frequency ranges and EEG channels to accurately diagnose PD. Finally, with a fewer number of features (11 features), we achieved a maximum classification accuracy (ARKF) of ~99.9%. The most prominent frequency range of EEG signals has been identified, and we have found that high classification accuracy depends on low-frequency signal components (0-4 Hz). Moreover, the most informative signals were mainly received from the right hemisphere of the head (F8, P8, T8, FC6). Furthermore, we assessed the accuracy of the diagnosis of PD using three different lengths of EEG data (150-1000 samples). Because the computational complexity is reduced by reducing the input data. As a result, we have achieved a maximum mean accuracy of 99.9% for a sample length (LEEG) of 1000 (~7.8 seconds), 98.2% with a LEEG of 800 (~6.2 seconds), and 79.3% for LEEG = 150 (~1.2 seconds). By reducing the number of features and segment lengths, the computational cost of classification can be reduced. Lower-performance smart ML sensors can be used in IoT environments for enhances human resilience to PD.Comment: 19 pages, 10 figures, 2 table

Intelligent IoT Framework for Indoor Healthcare Monitoring of Parkinson's Disease Patient

Parkinson’s disease is associated with high treatment costs, primarily attributed to the needs of hospitalization and frequent care services. A study reveals annual per-person healthcare costs for Parkinson’s patients to be 21,482,withanadditional29,695 burden to society. Due to the high stakes and rapidly rising Parkinson’s patients’ count, it is imperative to introduce intelligent monitoring and analysis systems. In this paper, an Internet of Things (IoT) based framework is proposed to enable remote monitoring, administration, and analysis of patient’s conditions in a typical indoor environment. The proposed infrastructure offers both static and dynamic routing, along with delay analysis and priority enabled communications. The scheme also introduces machine learning techniques to detect the progression of Parkinson’s over six months using auditory inputs. The proposed IoT infrastructure and machine learning algorithm are thoroughly evaluated and a detailed analysis is performed. The results show that the proposed scheme offers efficient communication scheduling, facilitating a high number of users with low latency. The proposed machine learning scheme also outperforms state-of-the-art techniques in accurately predicting the Parkinson’s progression

Alpha-Synuclein: Insight into the Hallmark of Parkinson\u27s Disease as a Target for Quantitative Molecular Diagnostics and Therapeutics

Parkinson’s disease (PD) is the second-most common neurodegenerative disease after Alzheimer’s disease. With 500,000 individuals currently living with Parkinson’s and nearly 60,000 new cases diagnosed each year, this disease causes significant financial burden on the healthcare system - amassing to annual expenditures totaling 200 billion dollars; predicted to increase through 2050. The disease phenotype is characterized by a combination of a resting tremor, bradykinesia, muscular rigidity, and depression due to dopaminergic neuronal death in the midbrain. The cause of the neurotoxicity has been largely discussed, with strong evidence suggesting that the protein, alpha-Synuclein, is a key factor. Under native conditions, alpha-Synuclein can be found localized at synaptic terminals where it is hypothesized to be involved in vesicle trafficking and recycling. However, its biochemical profile reveals a hydrophobic region that, once subjected to insult, initiates an aggregation cascade. Oligomeric species—products of the aggregation cascade—demonstrate marked neurotoxicity in dopaminergic neurons and illustrate migratory potential to neighboring healthy neurons, thereby contributing to progressive neurodegeneration. The current golden standard for PD diagnostics is a highly qualitative system involving a process-by-elimination with accuracy that is contingent upon physician experience. This, and a lack of standardized clinical testing procedures, lends to a 25% misdiagnosis rate. Even under circumstances of an accurate PD diagnosis, the only treatment options are pharmacologics that have a wide range of adverse side effects and ultimately contribute to systemic metabolic dysfunction. Thus, the research presented in this thesis seeks to overcome these current challenges by providing (1) a quantitative diagnostic platform and (2) a biomolecular therapeutic, towards oligomeric alpha-Synuclein. Aim 1: serves as a proof-of-concept for the use of catalytic nucleic acid moieties, deoxyribozymes and aptamers, to quantify alpha-Synuclein in a novel manner and explore the ability to detect oligomeric cytotoxic species. The cost-effective nature of these sensors allows for continued optimization. Aim 2: serves to establish a potential therapy that can abrogate alpha-synuclein oligomerization and toxicity through use of a modified Protein Disulfide Isomerase (PDI) peptide when introduced to live cells treated to simulate pre-parkinsonian pathology